It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic and interactive live educational program will feature renowned faculty experts who will lead an interactive discussion of important evidence supporting the use of individualized oral combination therapy to attain glycemic control while minimizing weight gain, as well as hypoglycemic and CV risk. 

Learning Objectives

  • Set glycemic goals and sequence oral treatments based on the latest management guidelines in individuals with T2DM
  • Select oral combination antidiabetic therapies to maximize glycemic efficacy while reducing the risk of hypoglycemia, weight gain, and cardiovascular events in individuals with normal and impaired kidney function
  • Appropriately utilize available oral fixed-dose combinations to maximize adherence to treatment  

Faculty Disclosures

Richard E. Pratley, MD

Contracted Research for Lexicon Pharmaceuticals, Inc.; Ligand Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk Inc.; Sanofi US; and Takeda Pharmaceuticals U.S.A, Inc. Speaker’s Bureau for Novo Nordisk Inc. and Takeda Pharmaceuticals U.S.A, Inc. Services Provided for Promotional Purposes (Not for CME/CE Services) for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eisai Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A, Inc. 

Robert R. Henry, MD, FRCP (C), FRCE, FACE, FACN

Boehringer Ingelheim; Diasome Pharmaceuticals, Inc; Intarcia Therapeutics; Ionis Pharmaceuticals; Johnson & Johnson; Lexicon; Merck & Co., Inc.; and Sanofi-Aventis. Contracted Research for AstraReal; Eli Lilly and Company; Hitachi; Novo Nordisk Inc.; and ViaCyte, Inc.

Frank Lavernia, MD

Advisory Board for Sanofi US. Speaker's Bureau for Janssen Pharmaceuticals.


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

pmiCME designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

pmiCME is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This program has been approved for 1.50 contact hours of continuing education, which includes 0.65 hour of pharmacology.

Commercial Supporter

Merck & Co., Inc.

Education Partner


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.